Wall Street brokerages expect Zoetis Inc. (NYSE:ZTS) to report $0.63 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Zoetis’ earnings. The lowest EPS estimate is $0.62 and the highest is $0.64. Zoetis posted earnings of $0.52 per share in the same quarter last year, which would indicate a positive year over year growth rate of 21.2%. The business is scheduled to announce its next quarterly earnings results on Wednesday, November 1st.
According to Zacks, analysts expect that Zoetis will report full-year earnings of $2.34 per share for the current year, with EPS estimates ranging from $2.30 to $2.37. For the next year, analysts anticipate that the business will report earnings of $2.68 per share, with EPS estimates ranging from $2.59 to $2.74. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Zoetis.
Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share for the quarter, hitting the consensus estimate of $0.53. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The business had revenue of $1.27 billion for the quarter, compared to analyst estimates of $1.27 billion. During the same quarter last year, the company earned $0.49 EPS. The business’s quarterly revenue was up 5.0% on a year-over-year basis.
Several research analysts recently commented on the company. BidaskClub upgraded Zoetis from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Goldman Sachs Group, Inc. (The) restated a “neutral” rating and set a $62.00 price objective on shares of Zoetis in a research note on Monday, August 7th. Cantor Fitzgerald restated a “buy” rating and set a $75.00 price objective on shares of Zoetis in a research note on Wednesday, September 6th. Cowen and Company set a $70.00 price objective on Zoetis and gave the company a “buy” rating in a research note on Monday, July 17th. Finally, Stifel Nicolaus restated a “buy” rating and set a $65.00 price objective on shares of Zoetis in a research note on Friday, September 1st. One research analyst has rated the stock with a sell rating, five have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $65.44.
ILLEGAL ACTIVITY NOTICE: “Zacks: Brokerages Anticipate Zoetis Inc. (ZTS) to Announce $0.63 Earnings Per Share” was originally published by Ticker Report and is owned by of Ticker Report. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/2887056/zacks-brokerages-anticipate-zoetis-inc-zts-to-announce-0-63-earnings-per-share.html.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Guardian Life Insurance Co. of America boosted its stake in shares of Zoetis by 0.7% during the 1st quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock worth $102,000 after acquiring an additional 13 shares in the last quarter. Sii Investments Inc. WI boosted its stake in shares of Zoetis by 0.3% during the 1st quarter. Sii Investments Inc. WI now owns 7,161 shares of the company’s stock worth $383,000 after acquiring an additional 23 shares in the last quarter. Argent Trust Co boosted its stake in shares of Zoetis by 0.8% during the 1st quarter. Argent Trust Co now owns 4,132 shares of the company’s stock worth $221,000 after acquiring an additional 32 shares in the last quarter. Ironwood Investment Management LLC boosted its stake in shares of Zoetis by 0.7% during the 2nd quarter. Ironwood Investment Management LLC now owns 6,870 shares of the company’s stock worth $429,000 after acquiring an additional 48 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. boosted its stake in shares of Zoetis by 1.3% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 4,201 shares of the company’s stock worth $262,000 after acquiring an additional 55 shares in the last quarter. 93.31% of the stock is owned by institutional investors and hedge funds.
Shares of Zoetis (NYSE ZTS) traded down 0.008% during midday trading on Friday, hitting $65.275. The stock had a trading volume of 1,026,246 shares. The stock has a 50 day moving average of $61.83 and a 200-day moving average of $59.09. The company has a market cap of $31.93 billion, a P/E ratio of 36.899 and a beta of 1.02. Zoetis has a one year low of $46.86 and a one year high of $65.50.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.